A prospective study of docetaxel-associated pain syndrome

[1]  H. Woodrow,et al.  : A Review of the , 2018 .

[2]  S. Verma,et al.  Taxane-induced arthralgia and myalgia: A literature review , 2017, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[3]  B. Hutton,et al.  Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer—a systematic review , 2016, Supportive Care in Cancer.

[4]  B. Hutton,et al.  Treatment of taxane acute pain syndrome (TAPS) in cancer patients receiving taxane-based chemotherapy—a systematic review , 2016, Supportive Care in Cancer.

[5]  E. Stacey,et al.  Which pain intensity scale from the Brief Pain Inventory correlates most highly with functional interference scores in patients experiencing taxane-induced arthralgia and myalgia? , 2016, Supportive Care in Cancer.

[6]  R. Chow,et al.  Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis , 2016, Supportive Care in Cancer.

[7]  P. Niravath.  Aromatase inhibitor-induced arthralgia: a review. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  P. Novotny,et al.  Further data supporting that paclitaxel‐associated acute pain syndrome is associated with development of peripheral neuropathy , 2012, Cancer.

[9]  P. Novotny,et al.  Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  P. Mantyh,et al.  The Paclitaxel Acute Pain Syndrome: Sensitization of Nociceptors as the Putative Mechanism , 2007, Cancer journal.

[11]  D. Ghersi,et al.  Taxanes for adjuvant treatment of early breast cancer. , 2007, The Cochrane database of systematic reviews.

[12]  Michael Hawkins,et al.  Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  E. Bruera,et al.  Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. , 2004, Cytokine.

[14]  M. Markman.  Prevention of paclitaxel-associated arthralgias and myalgias. , 2003, The journal of supportive oncology.

[15]  M. J. van den Bent,et al.  Peripheral neurotoxicity induced by docetaxel , 1996, Neurology.

[16]  Cristina Saura,et al.  Nanoparticle albumin-bound (nab™)-paclitaxel: improving efficacy and tolerability by targeted drug delivery in metastatic breast cancer , 2010 .

[17]  Xueri Li,et al.  Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients:The FNCLCC PACS 01 Trial , 2009 .

[18]  A. Seidman,et al.  Taxanes in breast cancer: An update , 2007, Current oncology reports.

[19]  M. Friedrich,et al.  Taxanes in the first-line chemotherapy of metastatic breast cancer: review. , 2004, European journal of gynaecological oncology.

[20]  H. Hartung,et al.  Chemotherapy-induced peripheral neuropathy , 2002, Journal of Neurology.